循环肿瘤DNA在膀胱癌中的研究进展及临床价值  

Research progress and clinical value of circulating tumor DNA in bladder cancer

作　　者：张勇[1] 李伟宏 王毓斌 ZHANG Yong;LI Weihong;WANG Yubin(The 5th Clinical Medical College of Shanxi Medical University,Taiyuan 030012;Department of Urology,Shanxi Provincial People's Hospital,Taiyuan 030012,China)

机构地区：[1]山西医科大学第五临床医学院,山西太原030012 [2]山西省人民医院泌尿外科,山西太原030012

出　　处：《现代泌尿外科杂志》2024年第6期555-559,共5页Journal of Modern Urology

基　　金：山西省自然科学研究面上项目(No.202103021224375);山西省留学人员科技活动择优资助项目(No.2022047);山西省回国留学人员科研资助项目(No.2022-204)。

摘　　要：随着生物技术的发展,液体活检技术在肿瘤方面的研究逐渐深入,循环肿瘤DNA(ctDNA)作为液体活检的主要方式之一,以其非侵入性、可重复性及可早期发现病变等特点备受关注。目前有研究表明ctDNA在膀胱癌(BCa)的早期诊断和分级、靶向治疗的选择和疗效分析、肿瘤的复发及进展等方面有一定的潜能,本文结合ctDNA的特点及其近年来在BCa中的研究进展和临床价值进行综述。ctDNA检测技术近年不断发展,人们在测序、突变测定技术发展及在增强其作为癌症检测生物标志物能力方面做出多项进展与尝试。对血浆样本中ctDNA的检测有助于在早期BCa的诊断中实现准确分类,但由于ctDNA含量低,需要更先进检测技术的支持;基于靶向测序的ctDNA分析是预测非肌层浸润性膀胱癌(NMIBC)患者疾病复发和侵袭性的一种有希望的方法。在晚期BCa患者中,可以应用ctDNA收集特有突变类型的特点,有针对性地指导用药、调整治疗及监测预后。尽管ctDNA在BCa的应用仍存在挑战,但已表现出广泛的应用前景。With the development of biotechnology,research on liquid biopsy of tumor has been deepened.As one of the major methods of liquid biopsy,circulating tumor DNA(ctDNA)has attracted much attention due to its non-invasive,safe and early detection of lesions.At present,studies have shown that ctDNA has certain potential in the early diagnosis and grading of bladder cancer,selection and efficacy analysis of targeted therapy,and recurrence and progression of tumors.This paper reviews the characteristics of ctDNA,research progress,detection methods and its clinical value in the diagnosis,treatment and prognosis of bladder cancer.In recent years,the development of ctDNA detection technology has made many advances and attempts in the development of sequencing and mutation detection technologies and in enhancing its ability as a biological marker for cancer detection.Detection of ctDNA in plasma samples can help achieve accurate classification in the diagnosis of early-stage bladder cancer,but requires the support of more advanced detection technologies due to low levels.Targeted sequencing-based ctDNA analysis is a promising method for predicting disease recurrence and aggressiveness in NMIBC patients.In patients with advanced bladder cancer,ctDNA can be used to collect the characteristics of mutation types to guide medication,adjust treatment and monitor prognosis.Although there are still challenges of ctDNA in the application of bladder cancer,it has shown a wide range of application prospects.

关 键 词：液体活检 循环肿瘤DNA 膀胱癌 测序 靶向 突变 辅助治疗 靶向治疗 

分 类 号：R737.14[医药卫生—肿瘤]